Literature DB >> 2564378

Restriction fragment length polymorphism of the L-myc gene and susceptibility to metastasis in renal cancer patients.

Y Kakehi1, O Yoshida.   

Abstract

We examined Southern blot analyses of normal and tumor DNAs from 50 patients with sporadic renal cancer, using the human L-myc oncogene fragment as a hybridization probe. Our purpose was to study the relationship between the restriction fragment length polymorphism (RFLP) of the L-myc and the frequencies of metastases. There was no individual difference in patterns of L-myc RFLP between normal and tumor-tissue DNAs digested with EcoRI. The patients were classified into 3 genetic types according to the polymorphic patterns defined by the 2 alleles [10-kilobase (kb) and 6.6-kb fragments]. The relative ratios of the 3 genotypes in the renal cancer patients were similar to those seen in healthy Japanese. However, of 16 patients who exhibited distant organ metastases at the time of surgery, only one was a 10-kb fragment homozygote. The incidence of distant metastases in 10-kb homozygotes was significantly lower than that in 6.6-kb homozygotes plus heterozygotes (p = 0.06). These results basically correspond to the previous findings in the lung cancer patients, and suggest that L-myc RFLP is a widely applicable genetic marker to predict prognosis in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564378     DOI: 10.1002/ijc.2910430307

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.

Authors:  R Dolcetti; S Pelucchi; R Maestro; S Rizzo; A Pastore; M Boiocchi
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

2.  Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor.

Authors:  I Zborovskaya; A Gasparian; M Kitaeva; B Polotzky; N Tupitzin; Z Machaladze; S Gerasimov; M Shtutman; M Jakubovskaya; M Davidov; A Tatosyan
Journal:  Clin Exp Metastasis       Date:  1996-11       Impact factor: 5.150

3.  Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls.

Authors:  G Chenevix-Trench; M Southall; C Kidson
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

4.  MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer.

Authors:  K M Fong; Y Kida; P V Zimmerman; P J Smith
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

5.  L-myc restriction fragment length polymorphism in Japanese patients with esophageal cancer.

Authors:  K Shibuta; H Inoue; K Sato; A Matsuyama; H Ueo; Y Tanaka; K Mafune; G F Barnard; M Mori
Journal:  Jpn J Cancer Res       Date:  2000-02

6.  Different susceptibility of each L-myc genotype to esophageal cancer risk factors.

Authors:  H Kumimoto; N Hamajima; K Nishizawa; Y Nishimoto; K Matsuo; H Harada; M Shinoda; S Hatooka; K Ishizaki
Journal:  Jpn J Cancer Res       Date:  2001-07

7.  Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis.

Authors:  A Weston; N E Caporaso; L S Perrin; H Sugimura; S Tamai; T G Krontiris; B F Trump; R N Hoover; C C Harris
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

8.  Restriction fragment length polymorphism of the L-myc gene in oral cancer patients.

Authors:  D Saranath; R G Panchal; R Nair; A R Mehta; V Sanghavi; M G Deo
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

9.  Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma.

Authors:  P E Crossen; M J Morrison; B M Colls
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

10.  Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients.

Authors:  T Tefre; A L Børresen; S Aamdal; A Brøgger
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.